Nuvilex, Inc. (OTCQB: NVLX) announced today that affiliate, SG Austria, a leading cell encapsulation company based in Singapore, has been invited to participate in the Phacilitate Cell & Gene Therapy Forum Asia 2011, an exclusive meeting to facilitate advances in science through interactions between senior level company executives, scientists and clinicians.
The 3-day conference for executives will focus on “in-depth exploration and clarification of the latest developments in regulatory guidelines and legislation for cell & gene therapy and tissue engineered products in Asia.” This 1st Asian Cell & Gene Therapy meeting aims to advance the production of safe, commercially viable products across Asia, building on the substantial success it has achieved in the U.S. over the past decade. The conference will be held September 19th-21st, 2011 at The Marina Bay Sands Hotel in Singapore.
Dr. John Dangerfield, the SG Austria COO, will be presenting the Company’s Cell-in-a-Box® Technology. The presentation by Dr. Dangerfield will focus on clinical experience using the live-cell encapsulation technology in the treatment of various forms of cancer as well as its use for other biomedical applications including stem cells. Overall, the Phacilitate Asia 2011 meeting is aimed at key opinion leaders and senior decision-makers.
Dr. Robert Ryan, President and CEO of Nuvilex, said, “Nuvilex is energized by the important advances SG Austria has accomplished over the past decade and is extremely pleased they will be showcasing the cell encapsulation technology at this important gene and cell therapy conference. It is a testament for us that SG Austria’s executives have been recognized as key Thought Leaders in the areas of Cell and Gene Therapy as a result of their substantial contributions. The invitation to present at such an important meeting underscores the considerable value of our live cell encapsulation platform as a key technology for a multitude of therapeutic applications of cell therapy."
Nuvilex, Inc. (OTCQB: NVLX) is an innovative biotechnology and natural products company. Nuvilex’s leading oncology offerings under development are moving forward using the company’s industry-leading live-cell encapsulation technology. The pancreatic cancer treatment is being readied for clinical trials and other advances are in progress with the live-cell encapsulation technology. Current natural products also being expanded include Gluten-Free Cinnergen™, Cinnechol™ and others to enhance a healthy lifestyle. Additional offerings include products designed for cosmetic use, flu treatment, and heavy-metal-free tattoo inks. Developments are planned for Citroxin™ and Oraphyte™, Nuvilex’s antimicrobial and antinematodal agents.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.Business Wire
Last updated on: 24/08/2011
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.